Pflug Koory LLC Raises Position in Cencora, Inc. (NYSE:COR)

Pflug Koory LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,160 shares of the company’s stock after buying an additional 75 shares during the quarter. Pflug Koory LLC’s holdings in Cencora were worth $261,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COR. Public Sector Pension Investment Board lifted its position in shares of Cencora by 39.4% during the second quarter. Public Sector Pension Investment Board now owns 4,508 shares of the company’s stock worth $1,016,000 after purchasing an additional 1,274 shares in the last quarter. Evergreen Capital Management LLC lifted its holdings in Cencora by 4.7% in the 2nd quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company’s stock worth $258,000 after buying an additional 52 shares in the last quarter. Marshall Wace LLP purchased a new position in Cencora in the 2nd quarter valued at about $1,539,000. MBB Public Markets I LLC grew its stake in shares of Cencora by 920.0% during the second quarter. MBB Public Markets I LLC now owns 12,648 shares of the company’s stock valued at $2,850,000 after acquiring an additional 11,408 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Cencora by 4.0% during the second quarter. The Manufacturers Life Insurance Company now owns 489,238 shares of the company’s stock worth $110,225,000 after acquiring an additional 18,935 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,187 shares of company stock worth $17,790,912 in the last three months. 15.80% of the stock is owned by insiders.

Cencora Stock Performance

Shares of NYSE COR opened at $248.45 on Friday. The stock has a market capitalization of $48.02 billion, a P/E ratio of 33.08, a P/E/G ratio of 1.54 and a beta of 0.49. The firm’s 50-day moving average price is $237.51 and its two-hundred day moving average price is $234.66. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 29.29%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on COR shares. Evercore ISI raised their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday. Barclays increased their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Finally, UBS Group increased their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.00.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.